ANO1 and ovarian carcinoma: Other groups have likewise reported enhanced drug sensitivity when combining BI-D1870 with cisplatin in TMEM16A- overexpressing head and neck cancer [49], with paclitaxel in ovarian cancer cells [50] or with venetoclax/azacitidine in acute myeloid leukaemia [51].